Ken Griffin Omega Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.22 - $2.25 $13,908 - $25,650	-11,400 Reduced 65.9%	5,900 $7,000
Q2 2024 Aug 14, 2024	BUY	$1.86 - $3.2 $11,718 - $20,160	6,300 Added 57.27%	17,300 $35,000
Q1 2024 May 15, 2024	BUY	$2.73 - $5.32 $30,030 - $58,520	11,000 New	11,000 $40,000
Q3 2023 Nov 14, 2023	BUY	$2.15 - $5.68 $33,110 - $87,472	15,400 Added 481.25%	18,600 $39,000
Q2 2023 Aug 14, 2023	SELL	$5.6 - $9.66 $25,760 - $44,436	-4,600 Reduced 58.97%	3,200 $17,000
Q1 2023 May 15, 2023	SELL	$4.81 - $10.95 $6,252 - $14,234	-1,300 Reduced 14.29%	7,800 $47,000
Q4 2022 Feb 14, 2023	SELL	$4.22 - $7.05 $13,926 - $23,265	-3,300 Reduced 26.61%	9,100 $51,000
Q3 2022 Nov 14, 2022	BUY	$3.63 - $6.65 $45,012 - $82,460	12,400 New	12,400 $67,000

43.4M

25.8K

Ticker OMGA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,853,400
Market Cap $37.8M
Description
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.